Serologic Responses Following Sars-Cov-2 Vaccination and Factors Influencing It in Patients with Hematological Malignant and Non-Malignant Diseases - a Prospective Multicentric Study

Background Patients with hematologic malignancy have a higher risk of death from COVID-19 compared to the general population. A blunted immune response from both the underlying disease and applied treatment may contribute to development of more severe forms of COVID-19, absence of seroconversion, pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sertić, Zrinka, Lucijanic, Marko, Bašić-Kinda, Sandra, Serventi Seiwerth, Ranka, Periša, Vlatka, Sertić, Dubravka, Coha, Bozena, Pulanic, Drazen, Šegulja, Dragana, Rogić, Dunja, Valkovic, Toni, Aurer, Igor, Durakovic, Nadira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
623.Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701600/
http://dx.doi.org/10.1182/blood-2021-153573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701600/
http://dx.doi.org/10.1182/blood-2021-153573

Ejemplares similares